elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38764273-D49E2DBE-C414-43BA-BBFE-DE73DA58D2CD
Q38764273-D49E2DBE-C414-43BA-BBFE-DE73DA58D2CD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38764273-D49E2DBE-C414-43BA-BBFE-DE73DA58D2CD
Ocular toxicities of MEK inhibitors and other targeted therapies.
P2860
Q38764273-D49E2DBE-C414-43BA-BBFE-DE73DA58D2CD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38764273-D49E2DBE-C414-43BA-BBFE-DE73DA58D2CD
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
db238e25669e133191c066cde2f5c480fe416d1b
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.